UK Biotech Co. Closes Latest Funding Round With $84M
U.K.-based Artios Pharma Ltd., a DNA damage response company developing treatments for cancer, announced Friday that it has completed an $84 million (£65 million) series B funding round....To view the full article, register now.
Already a subscriber? Click here to view full article